Silence Therapeutics plc SEC filings SLN
Silence Therapeutics plc has 275 filings in SEC EDGAR's recent list, going back to Jan 5, 2010. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (material agreement, regulation fd disclosure).
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 19, 2026 | Oct 18, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 12, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 16, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 23, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Other events
|
Jun 11, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Other events
|
May 18, 2026 | May 18, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Dec 22, 2025 | Dec 14, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 22, 2025 | Dec 18, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 15, 2025 | Dec 14, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Other events
|
Oct 23, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 14, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 27, 2025 | Jun 26, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 6, 2025 | May 5, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 27, 2025 | Feb 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 2, 2025 | Jan 2, 2025 |
| 6-K | Current report (foreign issuer) | Dec 9, 2024 | Dec 9, 2024 |
| 6-K | Current report (foreign issuer) | Nov 18, 2024 | Nov 18, 2024 |
| 6-K | Current report (foreign issuer) | Nov 14, 2024 | Sep 30, 2024 |
| 6-K | Current report (foreign issuer) | Aug 15, 2024 | Jun 30, 2024 |
| 6-K | Current report (foreign issuer) | Jun 27, 2024 | Jun 27, 2024 |
| 6-K | Current report (foreign issuer) | Jun 24, 2024 | Jun 24, 2024 |
| 6-K | Current report (foreign issuer) | Jun 20, 2024 | Jun 20, 2024 |
| 6-K | Current report (foreign issuer) | May 17, 2024 | May 17, 2024 |
| 6-K | Current report (foreign issuer) | May 16, 2024 | Mar 31, 2024 |
| 6-K | Current report (foreign issuer) | May 1, 2024 | May 1, 2024 |
| 6-K | Current report (foreign issuer) | Apr 29, 2024 | Apr 29, 2024 |
| 6-K | Current report (foreign issuer) | Apr 15, 2024 | Apr 15, 2024 |
| 6-K | Current report (foreign issuer) | Mar 13, 2024 | Mar 13, 2024 |
| 6-K | Current report (foreign issuer) | Feb 23, 2024 | Feb 23, 2024 |
| 6-K | Current report (foreign issuer) | Feb 6, 2024 | Feb 5, 2024 |
| 6-K | Current report (foreign issuer) | Dec 1, 2023 | Dec 1, 2023 |
| 6-K | Current report (foreign issuer) | Nov 14, 2023 | Nov 14, 2023 |
| 6-K | Current report (foreign issuer) | Nov 1, 2023 | Nov 1, 2023 |
| 6-K/A | Filing | Aug 29, 2023 | Aug 29, 2023 |
| 6-K | Current report (foreign issuer) | Aug 16, 2023 | Aug 16, 2023 |
| 6-K | Current report (foreign issuer) | Jul 11, 2023 | Jul 11, 2023 |
| 6-K | Current report (foreign issuer) | Jul 3, 2023 | Jul 3, 2023 |
| 6-K | Current report (foreign issuer) | May 16, 2023 | Mar 31, 2023 |
| 6-K | Current report (foreign issuer) | May 4, 2023 | May 4, 2023 |
| 6-K | Current report (foreign issuer) | May 1, 2023 | May 1, 2023 |
| 6-K | Current report (foreign issuer) | Apr 27, 2023 | Apr 27, 2023 |
| 6-K | Current report (foreign issuer) | Mar 28, 2023 | Mar 28, 2023 |
| 6-K | Current report (foreign issuer) | Jan 12, 2023 | Jan 12, 2023 |
| 6-K | Current report (foreign issuer) | Nov 10, 2022 | Nov 10, 2022 |
| 6-K | Current report (foreign issuer) | Nov 7, 2022 | Nov 7, 2022 |
| 6-K | Current report (foreign issuer) | Sep 29, 2022 | Sep 29, 2022 |
| 6-K | Current report (foreign issuer) | Aug 16, 2022 | Aug 16, 2022 |
| 6-K | Current report (foreign issuer) | Aug 12, 2022 | Aug 12, 2022 |
| 6-K | Current report (foreign issuer) | Aug 11, 2022 | Aug 11, 2022 |
| 6-K | Current report (foreign issuer) | Jun 14, 2022 | Jun 14, 2022 |
| 6-K | Current report (foreign issuer) | May 16, 2022 | May 16, 2022 |
| 6-K | Current report (foreign issuer) | May 16, 2022 | May 16, 2022 |
| 6-K | Current report (foreign issuer) | Apr 25, 2022 | Apr 25, 2022 |
| 6-K | Current report (foreign issuer) | Apr 4, 2022 | Apr 4, 2022 |
| 6-K | Current report (foreign issuer) | Mar 23, 2022 | Mar 23, 2022 |
| 6-K | Current report (foreign issuer) | Feb 22, 2022 | Feb 22, 2022 |
| 6-K | Current report (foreign issuer) | Feb 9, 2022 | Feb 9, 2022 |
| 6-K | Current report (foreign issuer) | Dec 13, 2021 | Dec 13, 2021 |
| 6-K | Current report (foreign issuer) | Nov 26, 2021 | Nov 26, 2021 |
| 6-K | Current report (foreign issuer) | Nov 16, 2021 | Nov 16, 2021 |
| 6-K | Current report (foreign issuer) | Nov 1, 2021 | Nov 1, 2021 |
| 6-K | Current report (foreign issuer) | Oct 21, 2021 | Oct 21, 2021 |
| 6-K/A | Filing | Oct 15, 2021 | Oct 15, 2021 |
| 6-K | Current report (foreign issuer) | Oct 15, 2021 | Oct 15, 2021 |
| 6-K | Current report (foreign issuer) | Aug 12, 2021 | Aug 12, 2021 |
| 6-K | Current report (foreign issuer) | Aug 12, 2021 | Aug 12, 2021 |
| 6-K | Current report (foreign issuer) | Jun 15, 2021 | Jun 15, 2021 |
| 6-K | Current report (foreign issuer) | Jun 7, 2021 | Jun 7, 2021 |
| 6-K | Current report (foreign issuer) | May 25, 2021 | May 25, 2021 |
| 6-K | Current report (foreign issuer) | May 19, 2021 | May 19, 2021 |
| 6-K | Current report (foreign issuer) | May 7, 2021 | May 7, 2021 |
| 6-K | Current report (foreign issuer) | Apr 29, 2021 | Apr 29, 2021 |
| 6-K | Current report (foreign issuer) | Apr 28, 2021 | Apr 28, 2021 |
| 6-K | Current report (foreign issuer) | Apr 19, 2021 | Apr 19, 2021 |
| 6-K | Current report (foreign issuer) | Mar 30, 2021 | Mar 30, 2021 |
| 6-K | Current report (foreign issuer) | Feb 26, 2021 | Feb 26, 2021 |
| 6-K | Current report (foreign issuer) | Feb 17, 2021 | Feb 17, 2021 |
| 6-K | Current report (foreign issuer) | Feb 8, 2021 | Feb 5, 2021 |
| 6-K | Current report (foreign issuer) | Jan 6, 2021 | Jan 6, 2021 |
| 6-K | Current report (foreign issuer) | Nov 16, 2020 | Nov 16, 2020 |
| 6-K | Current report (foreign issuer) | Nov 2, 2020 | Nov 2, 2020 |
| 6-K | Current report (foreign issuer) | Oct 8, 2020 | Oct 8, 2020 |
| 6-K | Current report (foreign issuer) | Sep 14, 2020 | Sep 14, 2020 |
| 6-K | Current report (foreign issuer) | Sep 8, 2020 | Sep 8, 2020 |
Showing 92 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLN (Nasdaq), SLNCF (OTC)
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1479615
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.